Background: Data on pediatric second-line antiretroviral treatment (ART) outcomes are scarce, but essential to evaluate second-line and design third-line regimens. Methods: Children 12 years switching to second-line ART containing a protease inhibitor (PI) in Uganda were followed for 24 months. Viral load (VL) was determined at switch to second-line and every 6 months thereafter; genotypic resistance testing was done if VL ! 1000 cps/ml. Results: 60 children were included in the analysis; all had !1 drug resistance mutations at switch. Twelve children (20.0%) experienced treatment failure; no PI mutations were detected. Sub-optimal adherence and underweight were associated with treatment failure.
I N T R O D U C T I O N
Over the past 15 years, the number of HIV-infected children receiving antiretroviral treatment (ART) worldwide has increased dramatically [1] . As more children in low-and middle-income countries (LMIC) have access to ART, it is expected that the number of children who fail first-line treatment and require second-line options will rise. Historically, most children have been initiated on a first-line regimen consisting of a non-nucleoside reverse transcriptase inhibitor (NNRTI) with two nucleoside reverse transcriptase inhibitors (NRTI). The World Health Organization (WHO) recommends that children failing this firstline should switch to a second-line combining a protease inhibitor (PI) with an NRTI backbone [2] .
Data on second-line treatment outcomes among children living in LMIC are very limited [3] , but necessary in order to develop effective second-line and eventually third-line programs for this vulnerable population. Therefore, the aim of our study was to assess the virological outcomes of a cohort of children receiving second-line, PI-based treatment in Uganda, and to analyze the HIV drug resistance (HIVDR) profiles in children failing treatment.
M A T E R I A L S A N D M E T H O D S

Study population and procedures
This study is part of the Monitoring Antiretroviral Resistance in Children (MARCH) prospective cohort study in Uganda, following up on children 12 years of age, initiating first-or second-line ART. HIVDR data at first-and second-line ART initiation in this cohort have previously been described [4, 5] . For this analysis, we included children who received secondline ART for up to 24 months. This study has been approved by the ethical committees of the Joint Clinical Research Centre Uganda and the Uganda National Council of Science and Technology, and by the Academic Medical Center, University of Amsterdam in The Netherlands.
Study methods of this cohort have previously been described in detail [4] . Children on second-line ART were included if they had experienced clinical, immunological or virological failure of a previous first-line regimen. Determination of HIV-RNA viral load (VL) was performed at switch to second-line and every 6 months, and genotypic resistance testing (GRT) was performed retrospectively on samples with VL > 1000 cps/ml. Drug resistance mutations were scored according to the 2015 International AIDS Society-USA list [6] . Predicted reduced susceptibility to the prescribed second-line regimen was defined as a genotypic sensitivity score (GSS) <3; i.e. <3 fully susceptible drugs [7] . Second-line treatment failure was defined as a combined end point of either two consecutive VL measurements >1000 cps/ml 2 , or death. Children with a single VL > 1000 cps/ml at the last follow-up visit at 24 months did not have a confirmatory second measurement, and were also considered as having treatment failure. Thirty-day adherence was based on caregiver's report; adherence over time was calculated as the mean of these adherence reports, and was categorized as being suboptimal ( 95% adherence) or optimal (>95% adherence). Three-day adherence was a dichotomous variable reflecting whether a child had missed any pills in the past 3 days. Nutritional status was assessed using WHO Anthro (version 3.2. 
Statistical analysis
Patient characteristics were summarized for children with and without treatment failure. Continuous variables were compared using a student's t-test or Mann-Whitney U test, and categorical variables using a v 2 test or Fisher's exact test. The relatively small sample size did not allow for a multivariable regression analysis to identify independent predictors of treatment failure. A two-sided p-value of 0.05 was considered significant. Data were analyzed using Stata 12V R (StataCorp LP, TX, USA).
R E S U L T S From January 2010 to July 2011, 64 children were enrolled. All children received a ritonavir-boosted lopinavir (LPV/r)-based second-line regimen ( Table  1 ). All but four children had virological failure (VL > 1000 cps/ml) at the moment of switching to second-line ART. The proportion of children with virological suppression (VL < 1000 cps/ml) after 6, 12, 18 and 24 months is shown in Fig. 1 .
Treatment outcomes
Sixty children (93.8%) had at least two VL results during follow-up and were included in the analysis. Of these, 55 (91.7%) were in care and on treatment at the end of follow-up, 2 (3.3%) died, 1 (1.7%) was lost to follow up and 1 (1.7%) transferred out. Twelve children (20.0%) met the definition of treatment failure: five had two consecutive VL measurements >1000 cps/ml, five had one VL > 1000 cps/ ml at the last follow-up visit and two died, 14 and 16 months after second-line initiation (supplementary Table S1 , available at Journal of Tropical Pediatrics online).'
Predictors of virological failure Low weight-for-age z-scores (WAZ < À2) at second-line initiation were present in 4 of 12 (33.3%) children who experienced treatment failure, compared to 6 of 48 (12.5%) children who did not fail treatment (p ¼ 0.04). Twenty-five children (39.1%) reported to have missed one or more drug doses in the 3 days prior to one of their clinic visits, and this was more common in children with treatment failure compared to those without: 9/12 (75.0%) vs. 16/48 (33.3%), respectively (p ¼ 0.02, Table 1 ).
HIV drug resistance at switch to second-line GRT was successful in 50/60 (83.3%) children with a VL> 1000 cps/ml at switch to second-line. Mutations associated with NRTI, NNRTI and PI resistance were detected in 98.0%, 100% and 2.0%, respectively ( Fig. 2 ). M184V and K103N were the most prevalent mutations (n ¼ 48, 96.0% and n ¼ 22, 44.0%, respectively). Predicted reduced susceptibility to any of the prescribed second-line Virological suppression is defined as a viral load <1000 cps/ml. The number of children with viral load results was 60, 59, 57 and 55 after 6, 12, 18, and 24 months, respectively. antiretroviral drugs was not associated with treatment failure (Table 1) . The only child with a PI mutation at switch to second-line ART (Q58E, associated with tipranavir/ritonavir resistance) had a suppressed VL throughout follow-up on LPV/rbased second-line treatment.
HIV drug resistance at second-line failure GRT results were available for 11 of 12 children who experienced treatment failure during 24 months of follow-up; one child died without GRT results. Eight children harbored virus with dual resistance to NRTIs and NNRTIs at second-line treatment failure. In the three other children, no mutations were detected at second-line treatment failure, even though two of them had mutations at switch to second-line. Children with second-line failure had reduced susceptibility to a median of 5 NRTIs (range 0-7) and 3 NNRTIs (range 0-4) ( Table 2) . None of the children with treatment failure harbored virus with PI mutations (Table 2 and Fig. 2 ).
D I S C U S S I O N
This the first prospective cohort study reporting on HIVDR in children failing second-line ART in Africa. After 24 months of follow-up, 20% experienced virological failure, but no PI mutations were detected. Suboptimal adherence and underweight were associated with treatment failure.
Response to second-line ART The rate of treatment failure we found is low, compared to outcomes of other pediatric second-line cohorts in South-Africa and Kenya in which 30% Predicted susceptibility to second-line treatment was determined through calculation of the genotypic sensitivity score (GSS) using the Stanford algorithm version 7.0 [6] .
(VL > 400 cps/ml) and 38% (VL > 5000 cps/ml) experienced treatment failure after one to two years on second-line ART [9, 10] . Our results are comparable to results in a pediatric trial in high-income countries reporting that 19% did not achieve viral suppression [11] and to an adult cohort in six African countries (including our Ugandan study sites) in which 15% of participants did not have viral suppression after 24 months [12] . Interestingly, outcomes are much better than those of a cohort of children on first-line ART, enrolled at the same three study sites, in which 32.1% (92/287) failed after 24 months [13] . This difference may reflect the higher potency and higher genetic barrier of PIs compared to NNRTIs [14] , which were primarily used in the first-line cohort.
Predictors of virological failure Overall treatment adherence was suboptimal with almost 40% of children reporting to have missed a dose within 3 days before a clinic visit, which was associated with treatment failure (p ¼ 0.019). This is in accordance with a previous study in Uganda, in which children with poor adherence were 97% less likely to achieve viral suppression on second-line ART [15] . Reliably measuring treatment adherence is known to be complex [16, 17] . We chose to use 3-day and 30-day recall as this is one of the most widely used methods [16] , and because its use is feasible in resource-limited settings. However, this method may have overestimated adherence and possibly underestimated its effect on HIVDR. Our findings underline the importance of adherence support programs for children on ART, especially for children on second-line treatment. Prolonged exposure to inadequate drug levels because of missed drug doses is expected to lead to the development of PImutations in these children. This would be catastrophic as there are currently hardly any pediatric third-line options available in LMIC.
Children who were underweight at second-line ART initiation had significantly more virological failure than children with normal WAZ-scores. This association could be due to incorrect drug dosing in underweight children, or malabsorption leading to low plasma drug levels [18, 17] , or might be a proxy for other patient characteristics associated with treatment failure, such as clinical or immunological status. Results were available for 50 children at switch to second-line and 11 children at second-line failure. One child died and had no genotypic resistance testing results at treatment failure. NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor. [6] . Drugs of the second-line regimen are displayed in bold if mutation(s) against these agents were detected at second-line failure and had been selected for during second-line treatment. Drugs are displayed in italic when mutation(s) against these agents had been detected at first-line failure, but not at second-line failure, because mutations had been archived or because no sample was available. knowledge, only three other pediatric studies have reported on HIVDR at second-line treatment failure in LMIC. In Thailand, a retrospective cohort study reported that 6/53 (11.3%) children with treatment failure on second-line ART had PI mutations [20] . Two cross-sectional studies in Botswana and SouthAfrica showed that 7/28 (25.0%) and 0/3 (0%) children failing a LPV/r-based second-line regimen had PI mutations [21, 22] . Mutations against both NNRTIs and NRTIs were detected in all children with HIVDR at second-line failure. In two children, the NNRTI and NRTI mutations that were present at the time of switch were no longer detected at second-line failure. In these cases, the virus likely reverted to wild-type and mutations were archived after the exposure to associated drugs was stopped at switch to second-line.
HIV drug resistance
Implications
The number of children with treatment failure in our cohort was relatively low compared to results of children receiving first-line ART at the same study sites and comparable to a pediatric second-line cohort in high-resource settings. This indicates that the current PI-based second-line regimen is an adequate treatment option in children who have failed NNRTIbased ART. Suboptimal adherence appears to be the main factor explaining treatment failure, stressing the need for improved adherence support in HIV treatment programs, especially for children on secondline. Adherence support is not only important to improve treatment outcomes in the short term, but also to prevent the development of PI resistance over time. Exploring the reasons for suboptimal adherence, such as poor palatability of medication, pharmacy stock-outs or dependence on caregivers, is needed.
Our results are not directly applicable to young children on first-line PI-based treatment, which is now the recommended first-line treatment option for all children <3 years 2 . However, many countries have not yet implemented this strategy due to the high costs of PI-treatment and the need for a coldchain for the currently available syrup formulation. For these children, and for children !3 years, firstline NNRTI-based and second-line PI-based ART, as in our study, is the most common regimen sequence.
Limitations
Our study has some potential limitations. The sample size of 64 children was small, which prevented us from conducting a multivariable analysis. However, given the scarcity of data on this topic, our study adds substantially to the current knowledge on second-line pediatric treatment outcomes and the associations found might serve as a starting point for future research. Second, the failure rate of 20% could be an underestimation as failure rates may have been higher with more frequent VL testing. It may also be an overestimation as we, in accordance with other articles [9, 10] , considered children who had a single detectable VL at their last visit as having treatment failure. If we would not consider the five children with a single VL > 1000 cps/ml at the last clinic visit to be failing, the failure rate would be 11.7% (7/60). Finally, it has been suggested that PI resistance is not only caused by mutations in the pol gene, but also in other regions outside this gene [23, 24] . In children in whom we did not detect PI resistance, mutations could have been present in the env or gag gene leading to PI resistance. The clinical relevance of mutations outside the pol gene still needs further study.
In conclusion, outcomes of our cohort of Ugandan children on second-line ART were favorable, and no PI mutations were detected in children with treatment failure after 24 months of follow-up. Our results suggest that poor adherence, rather than the development of HIVDR, is the main mechanism of treatment failure in these children. Improving adherence is important to further improve second-line treatment results and to avoid development of HIVDR in the long term. 
